IL280479A - TLR7/8 antagonists and their use - Google Patents
TLR7/8 antagonists and their useInfo
- Publication number
- IL280479A IL280479A IL280479A IL28047921A IL280479A IL 280479 A IL280479 A IL 280479A IL 280479 A IL280479 A IL 280479A IL 28047921 A IL28047921 A IL 28047921A IL 280479 A IL280479 A IL 280479A
- Authority
- IL
- Israel
- Prior art keywords
- tlr7
- antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712439P | 2018-07-31 | 2018-07-31 | |
| PCT/EP2019/070312 WO2020025517A1 (en) | 2018-07-31 | 2019-07-29 | Tlr7/8 antagonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL280479A true IL280479A (en) | 2021-03-01 |
Family
ID=67660056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280479A IL280479A (en) | 2018-07-31 | 2021-01-28 | TLR7/8 antagonists and their use |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210300940A1 (enExample) |
| EP (1) | EP3830080A1 (enExample) |
| JP (2) | JP7491900B2 (enExample) |
| KR (2) | KR20260047300A (enExample) |
| CN (1) | CN112513024A (enExample) |
| AU (2) | AU2019313441B2 (enExample) |
| BR (2) | BR122023023308A2 (enExample) |
| CA (1) | CA3108099A1 (enExample) |
| IL (1) | IL280479A (enExample) |
| MX (2) | MX2021000093A (enExample) |
| SG (1) | SG11202100818RA (enExample) |
| TW (3) | TW202542153A (enExample) |
| WO (1) | WO2020025517A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3889145T (pt) * | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| EP4198031A1 (en) | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| CN111511729A (zh) * | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| AU2020250468A1 (en) * | 2019-03-29 | 2021-11-04 | Kinki University | Use of T-type calcium channel blocker for treating pruritus |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| WO2021052892A1 (en) * | 2019-09-16 | 2021-03-25 | F. Hoffmann-La Roche Ag | Piperidinyl amine compounds for the treatment of autoimmune disease |
| CR20220236A (es) | 2019-11-28 | 2022-10-03 | Bayer Pharma AG | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune |
| TW202200139A (zh) * | 2020-05-14 | 2022-01-01 | 德商馬克專利公司 | 用於治療冠狀病毒感染之tlr7/8拮抗劑 |
| EP4263535A1 (en) | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| KR20230171469A (ko) | 2021-04-16 | 2023-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN120603821A (zh) * | 2023-01-18 | 2025-09-05 | 苏州科睿思制药有限公司 | Enpatoran的晶型及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| CN104557913B (zh) * | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| MX2016006052A (es) | 2013-11-12 | 2016-07-18 | Hoffmann La Roche | Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos. |
| CN108290855A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| WO2017031427A1 (en) * | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| PT3889145T (pt) * | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| CN106632089B (zh) * | 2016-11-04 | 2019-06-18 | 中山大学 | 一类喹唑啉类化合物及其制备方法与应用 |
| ES2965044T3 (es) | 2017-07-18 | 2024-04-10 | Merck Patent Gmbh | Antagonistas de TLR7/8 y sus usos |
| CN111801015B (zh) * | 2017-12-12 | 2022-03-18 | 先正达参股股份有限公司 | 植物生长调节 |
| CN111511729A (zh) | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
-
2019
- 2019-07-29 CA CA3108099A patent/CA3108099A1/en active Pending
- 2019-07-29 MX MX2021000093A patent/MX2021000093A/es unknown
- 2019-07-29 KR KR1020267009849A patent/KR20260047300A/ko active Pending
- 2019-07-29 BR BR122023023308-5A patent/BR122023023308A2/pt unknown
- 2019-07-29 KR KR1020217005440A patent/KR102947440B1/ko active Active
- 2019-07-29 AU AU2019313441A patent/AU2019313441B2/en active Active
- 2019-07-29 US US17/250,489 patent/US20210300940A1/en active Pending
- 2019-07-29 EP EP19755290.4A patent/EP3830080A1/en active Pending
- 2019-07-29 JP JP2021505638A patent/JP7491900B2/ja active Active
- 2019-07-29 BR BR112021001618-0A patent/BR112021001618A2/pt unknown
- 2019-07-29 WO PCT/EP2019/070312 patent/WO2020025517A1/en not_active Ceased
- 2019-07-29 CN CN201980051004.3A patent/CN112513024A/zh active Pending
- 2019-07-29 SG SG11202100818RA patent/SG11202100818RA/en unknown
- 2019-07-30 TW TW114108280A patent/TW202542153A/zh unknown
- 2019-07-30 TW TW112144948A patent/TWI880472B/zh active
- 2019-07-30 TW TW108126963A patent/TWI827641B/zh active
-
2021
- 2021-01-06 MX MX2024013464A patent/MX2024013464A/es unknown
- 2021-01-28 IL IL280479A patent/IL280479A/en unknown
-
2024
- 2024-05-16 JP JP2024080418A patent/JP2024105611A/ja active Pending
- 2024-05-30 AU AU2024203629A patent/AU2024203629A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024203629A1 (en) | 2024-06-20 |
| JP2024105611A (ja) | 2024-08-06 |
| TWI880472B (zh) | 2025-04-11 |
| EP3830080A1 (en) | 2021-06-09 |
| TW202542153A (zh) | 2025-11-01 |
| JP7491900B2 (ja) | 2024-05-28 |
| TW202019899A (zh) | 2020-06-01 |
| BR122023023308A2 (pt) | 2024-02-20 |
| CN112513024A (zh) | 2021-03-16 |
| AU2019313441A1 (en) | 2021-03-18 |
| SG11202100818RA (en) | 2021-02-25 |
| TWI827641B (zh) | 2024-01-01 |
| BR112021001618A2 (pt) | 2021-04-27 |
| AU2019313441B2 (en) | 2024-05-23 |
| WO2020025517A1 (en) | 2020-02-06 |
| KR20210040085A (ko) | 2021-04-12 |
| US20210300940A1 (en) | 2021-09-30 |
| MX2021000093A (es) | 2021-03-25 |
| KR20260047300A (ko) | 2026-04-07 |
| JP2021533125A (ja) | 2021-12-02 |
| KR102947440B1 (ko) | 2026-04-03 |
| MX2024013464A (es) | 2024-12-06 |
| CA3108099A1 (en) | 2020-02-06 |
| TW202423913A (zh) | 2024-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280479A (en) | TLR7/8 antagonists and their use | |
| IL275463A (en) | TLR7/8 antagonists and their use | |
| IL272016A (en) | Pyrrolidine history and their use as TLR7/8 antagonists | |
| IL292692B1 (en) | Mrgprx2 antagonists and their uses | |
| IL264676B (en) | tlr 7/8 antagonists and their use | |
| ZA201803367B (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| ZA202101250B (en) | Novel crispr-associated protein and use thereof | |
| IL273954A (en) | Converted imidazopyridine amides and their use | |
| IL277749A (en) | Palladianolide compounds and their use | |
| IL274751A (en) | ILDR2 antagonists and combinations thereof | |
| GB201813312D0 (en) | Compounds and their therapeutic use | |
| IL279059A (en) | Methods and preparations for killing spores | |
| IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
| ZA202100092B (en) | Modified cas9 protein and use thereof | |
| IL282527A (en) | 5-Azaindazole history and their use | |
| IL282526A (en) | 5-Azaindazole history and their use | |
| PL3774141T3 (pl) | Hydrauliczny uchwyt rozprężny i jego zastosowanie | |
| IL288828A (en) | Binding factors - cd38 and their use | |
| GB201802122D0 (en) | Product and use | |
| IL276984A (en) | Insecticides and their use | |
| GB201906914D0 (en) | Substituted naphtahlene diimdes and their use | |
| IL280369A (en) | Myokines and their uses | |
| PL3860615T3 (pl) | Kompozycja doustna zawierająca B-escynę i jej zastosowanie | |
| IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
| GB201901413D0 (en) | Compositions and their use |